Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.
Molecular Oncology|May 27, 2022
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancersMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2023
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world dataMargherita Rimini, Lorenzo Fornaro, Sara Lonardi, et al.
BMC Cancer|April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 29, 2025
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON StudyCarolina Sciortino, Federico Nichetti, Francesca Bergamo, et al.
Cell Metabolism|December 18, 2024
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patientsFrancesca Ligorio, Andrea Vingiani, Tommaso Torelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 19, 2022
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinomaPaula Hoffmeister-Wittmann, Andreas Mock, Federico Nichetti, et al.
Targeted Oncology|May 1, 2024
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyMargherita Rimini, Gianluca Masi, Sara Lonardi, et al.
Hepatology (Baltimore, Md.)|November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCCAnna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.
Pageof 8